Use of radioactive iodine for thyroid cancer

JAMA

Volumn 306, Issue 7, 2011, Pages 721-728

  Haymart, Megan R ^a   Banerjee, Mousumi ^b   Stewart, Andrew K ^d   Koenig, Ronald J ^a   Birkmeyer, John D ^c   Griggs, Jennifer J ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d AMERICAN COLLEGE OF SURGEONS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOACTIVE IODINE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER STAGING; COMORBIDITY; CONTROLLED STUDY; DIFFERENTIATED THYROID CANCER; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THYROID CANCER; THYROIDECTOMY; TREATMENT INDICATION; TUMOR VOLUME; CLINICAL PRACTICE; COHORT ANALYSIS; FACTUAL DATABASE; HOSPITAL; MIDDLE AGED; RETROSPECTIVE STUDY; STATISTICS; THYROID TUMOR; UNITED STATES;

ADULT; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; HOSPITALS; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; RETROSPECTIVE STUDIES; THYROID NEOPLASMS; THYROIDECTOMY; UNITED STATES;

EID: 80051762060     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.1139     Document Type: Article

References (73)

1. Siegel R., Ward E., Brawley O., Jemal A. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212-236.
2. Varma V.M., Beierwaltes W.H., Nofal M.M., Nishiyama R.H., Copp J.E. Treatment of thyroid cancer: Death rates after surgery and after surgery followed by sodium iodide I-131. JAMA. 1970;214(8):1437-1442.
3. Chow S.M., Yau S., Kwan C.K., Poon P.C., Law S.C. Local and regional control in patients with papillary thyroid carcinoma: Specific indications of external radiotherapy and radioactive iodine according to T and N categories in AJCC 6th edition. Endocr Relat Cancer. 2006;13(4):1159-1172. (Pubitemid 46212570)
4. Jung T.S., Kim T.Y., Kim K.W., et al. Clinical features and prognostic factors for survival in patients with poorly differentiated thyroid carcinoma and comparison to the patients with the aggressive variants of papillary thyroid carcinoma. Endocr J. 2007;54(2):265-274. (Pubitemid 46798649)
5. Podnos Y.D., Smith D.D., Wagman L.D., Ellenhorn J.D. Survival in patients with papillary thyroid cancer is not affected by the use of radioactive isotope. J Surg Oncol. 2007;96(1):3-7. (Pubitemid 47015441)
6. Jonklaas J., Sarlis N.J., Litofsky D., et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid. 2006;16(12):1229-1242. (Pubitemid 46080167)
7. Hay I.D., McConahey W.M., Goellner J.R. Managing patients with papillary thyroid carcinoma: Insights gained from the Mayo Clinic's experience of treating 2512 consecutive patients during 1940 through 2000. Trans Am Clin Climatol Assoc. 2002;113:241-260.
8. Ito Y., Masuoka H., Fukushima M., et al. Excellent prognosis of patients with solitary T1N0M0 papillary thyroid carcinoma who underwent thyroidectomy and elective lymph node dissection without radioiodine therapy. World J Surg. 2010;34(6):1285-1290.
9. Mazzaferri E.L. What is the optimal initial treatment of low-risk papillary thyroid cancer (and why is it controversial)? Oncology (Williston Park). 2009;23(7):579-588.
10. Jonklaas J., Cooper D.S., Ain K.B., et al National Thyroid Cancer Treatment Cooperative Study Group. Radioiodine therapy in patients with stage I differentiated thyroid cancer. Thyroid. 2010;20(12):1423-1424.
11. Hay I.D. Managing patients with a preoperative diagnosis of AJCC/UICC stage I (T1N0M0) papillary thyroid carcinoma: East vs West, whose policy is best? World J Surg. 2010;34(6):1291-1293.
12. Cooper D.S., Doherty G.M., Haugen B.R., et al American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167-1214.
13. Cooper D.S., Doherty G.M., Haugen B.R., et al American Thyroid Association Guidelines Taskforce. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006;16(2):109-142.
14. Sherman S.I., Angelos P., Ball D.W., et al National Comprehensive Cancer Network. Thyroid carcinoma. J Natl Compr Canc Netw. 2005;3(3):404-457.
15. Sherman S.I., Angelos P., Ball D.W., et al National Comprehensive Cancer Network Thyroid Carcinoma Panel. Thyroid carcinoma. J Natl Compr Canc Netw. 2007;5(6):568-621. (Pubitemid 47057050)
16. Tuttle R.M., Ball D.W., Byrd D., et al National Comprehensive Cancer Network. Thyroid carcinoma. J Natl Compr Canc Netw. 2010;8(11):1228-1274.
17. Cobin R.H., Gharib H., Bergman D.A., et al; Thyroid Carcinoma Task Force; American Association of Clinical Endocrinologists; American College of Endocrinology. AACE/AAES medical/surgical guidelines for clinical practice: Management of thyroid carcinoma. Endocr Pract. 2001;7(3):202-220.
18. Raymond J.P., Izembart M., Marliac V., et al. Temporary ovarian failure in thyroid cancer patients after thyroid remnant ablation with radioactive iodine. J Clin Endocrinol Metab. 1989;69(1):186-190. (Pubitemid 19172445)
19. Brown A.P., Chen J., Hitchcock Y.J., Szabo A., Shrieve D.C., Tward J.D. The risk of second primary malignancies up to 3 decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab. 2008;93(2):504-515. (Pubitemid 351240823)
20. Sandeep T.C., Strachan M.W., Reynolds R.M., et al. Second primary cancers in thyroid cancer patients: A multinational record linkage study. J Clin Endocrinol Metab. 2006;91(5):1819-1825.
21. Solans R., Bosch J.A., Galofré P., et al. Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy. J Nucl Med. 2001;42(5):738-743. (Pubitemid 32453462)
22. Iyer N.G., Morris L.G., Tuttle R.M., Shaha A.R., Ganly I. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy [published online ahead of print March 22, 2011]. Cancer. doi:10.1002/cncr.26070.
23. Malpani B.L., Samuel A.M., Ray S. Quantification of salivary gland function in thyroid cancer patients treated with radioiodine. Int J Radiat Oncol Biol Phys. 1996;35(3):535-540. (Pubitemid 26242902)
24. Sawka A.M., Goldstein D.P., Brierley J.D., et al. The impact of thyroid cancer and post-surgical radioactive iodine treatment on the lives of thyroid cancer survivors: A qualitative study. PLoS One. 2009;4(1):e4191.
25. Burns J.A., Morgenstern K.E., Cahill K.V., Foster J.A., Jhiang S.M., Kloos R.T. Nasolacrimal obstruction secondary to I(131) therapy. Ophthal Plast Reconstr Surg. 2004;20(2):126-129.
26. Morgenstern K.E., Vadysirisack D.D., Zhang Z., et al. Expression of sodium iodide symporter in the lacrimal drainage system: Implication for the mechanism underlying nasolacrimal duct obstruction in I(131)-treated patients. Ophthal Plast Reconstr Surg. 2005;21(5):337-344. (Pubitemid 41464081)
27. Van Nostrand D., Neutze J., Atkins F. Side effects of "rational dose" iodine-131 therapy for metastatic well-differentiated thyroid carcinoma. J Nucl Med. 1986;27(10):1519-1527. (Pubitemid 17181262)
28. Hyer S., Vini L., O'Connell M., Pratt B., Harmer C. Testicular dose and fertility in men following I(131) therapy for thyroid cancer. Clin Endocrinol (Oxf) . 2002;56(6):755-758. (Pubitemid 34785906)
29. Molinaro E., Leboeuf R., Shue B., et al. Mild decreases in white blood cell and platelet counts are present 1 year after radioactive iodine remnant ablation. Thyroid. 2009;19(10):1035-1041.
30. Kloos R.T. Protecting thyroid cancer patients from untoward effects of radioactive iodine treatment. Thyroid. 2009;19(9):925-928.
31. Pace-Asciak P.Z., Payne R.J., Eski S.J., Walfish P., Damani M., Freeman J.L. Cost savings of patients with a MACIS score lower than 6 when radioactive iodine is not given. Arch Otolaryngol Head Neck Surg. 2007;133(9):870-873. (Pubitemid 47437273)
32. Davies L., Welch H.G. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006;295(18):2164-2167.
33. Chen A.Y., Jemal A., Ward E.M. Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer. 2009;115(16):3801-3807.
34. Raval M.V., Bilimoria K.Y., Stewart A.K., Bentrem D.J., Ko C.Y. Using the NCDB for cancer care improvement: An introduction to available quality assessment tools. J Surg Oncol. 2009;99(8):488-490.
35. Phillips JK, Stewart AK, eds. Facility Oncology Data Standards. Chicago, IL: Commission on Cancer; 2006.
36. Smedley BD, Stith AY, Nelson AR, eds. Unequal Treatment: Confronting Racial and Ethnic Disparities. Washington, DC: National Academies Press; 2003.
37. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 1987;40(5):373-383. (Pubitemid 17055592)
38. Deyo R.A., Cherkin D.C., Ciol M.A. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-619.
39. Greene F., Page D.L., Fleming I.D. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer; 2002.
40. Percy C, Fritz A, Jack A, eds, et al. International Classification of Diseases for Oncology. 3rd ed. Geneva, Switzerland: World Health Organization; 2000.
41. Snijders T.A.B., Bosker R.J. Multilevel Analysis. Thousands Oaks, CA: Sage; 1999.
42. Subramanian S., Jones K., Duncan C. Multilevel Methods for Public Health Research. New York, NY: Oxford University Press; 2003.
43. Normand S.T., Glickman M.E., Gatsonis C.A. Statistical methods for profiling providers of medical care: Issues and applications. J Am Stat Assoc. 1997;92(439):803-814.
44. Birkmeyer J.D., Sharp S.M., Finlayson S.R., Fisher E.S., Wennberg J.E. Variation profiles of common surgical procedures. Surgery. 1998;124(5):917-923. (Pubitemid 28520786)
45. Birkmeyer J.D., Siewers A.E., Finlayson E.V., et al. Hospital volume and surgical mortality in the United States. N Engl J Med. 2002;346(15):1128-1137. (Pubitemid 34984604)
46. Griggs J.J., Sorbero M.E., Ahrendt G.M., et al. The pen and the scalpel: Effect of diffusion of information on nonclinical variations in surgical treatment. Med Care. 2009;47(7):749-757.
47. Sirovich B., Gallagher P.M., Wennberg D.E., Fisher E.S. Discretionary decision making by primary care physicians and the cost of US health care. Health Aff (Millwood). 2008;27(3):813-823. (Pubitemid 351770251)
48. Hay I.D., Thompson G.B., Grant C.S., et al. Papillary thyroid carcinoma managed at the Mayo Clinic during 6 decades (1940-1999): Temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg. 2002;26(8):879-885. (Pubitemid 36920280)
49. Black W.C., Welch H.G. Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy. N Engl J Med. 1993;328(17):1237-1243. (Pubitemid 23115703)
50. National Cancer Institute. Surveillance, Epidemiology, and End Results. http://www.seer.cancer.gov/. Accessed March 8, 2010.
51. Hughes D.T., Haymart M.R., Miller B.S., Gauger P.G., Doherty G.M. The most commonly occurring papillary thyroid cancer in the United States is now a microcarcinoma in a patient older than 45 years. Thyroid. 2011;21(3):231-236.
52. Harach H.R., Franssila K.O., Wasenius V.M. Occult papillary carcinoma of the thyroid: A "normal" finding in Finland: A "normal" finding in FinlandA systematic autopsy study. Cancer. 1985;56(3):531-538. (Pubitemid 15035581)
53. Martinez-Tello F.J., Martinez-Cabruja R., Fernandez-Martin J., Lasso-Oria C., Ballestin-Carcavilla C. Occult carcinoma of the thyroid: A systematic autopsy study from Spain of 2 series performed with 2 different methods. Cancer. 1993;71(12):4022-4029. (Pubitemid 23172986)
54. Welch H.G., Black W.C. Overdiagnosis in cancer. J Natl Cancer Inst. 2010;102(9):605-613.
55. Wennberg J.E., Barnes B.A., Zubkoff M. Professional uncertainty and the problem of supplierinduced demand. Soc Sci Med. 1982;16(7):811-824. (Pubitemid 12059538)
56. Wennberg J.E. Understanding geographic variations in health care delivery. N Engl J Med. 1999;340(1):52-53. (Pubitemid 29024687)
57. Greenberg C.C., Lipsitz S.R., Neville B., et al. Receipt of appropriate surgical care for Medicare beneficiaries with cancer [published online ahead of print June 20, 2011]. Arch Surg. doi:10.1001/archsurg.2011.141.
58. Bonnet S., Hartl D., Leboulleux S., et al. Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: Implications for radioiodine treatment. J Clin Endocrinol Metab. 2009;94(4):1162-1167.
59. Sawka A.M., Thephamongkhol K., Brouwers M., Thabane L., Browman G., Gerstein H.C. Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab. 2004;89(8):3668-3676. (Pubitemid 39089119)
60. Lin H.W., Bhattacharyya N. Survival impact of treatment options for papillary microcarcinoma of the thyroid. Laryngoscope. 2009;119(10):1983-1987.
61. Brierley J., Tsang R., Panzarella T., Bana N. Prognostic factors and the effect of treatment with radioactive iodine and external beam radiation on patients with differentiated thyroid cancer seen at a single institution over 40 years. Clin Endocrinol (Oxf) . 2005;63(4):418-427. (Pubitemid 41442336)
62. Hay I.D. Selective use of radioactive iodine in the postoperative management of patients with papillary and follicular thyroid carcinoma. J Surg Oncol. 2006;94(8):692-700. (Pubitemid 44902068)
63. Roti E., degli Uberti EC, Bondanelli M, Braverman LE. Thyroid papillary microcarcinoma: a descriptive and meta-analysis study. Eur J Endocrinol. 2008;159(6):659-673.
64. Sisson J.C. Applying the radioactive eraser: I-131 to ablate normal thyroid tissue in patients from whom thyroid cancer has been resected. J Nucl Med. 1983;24(8):743-745. (Pubitemid 13016097)
65. Hay I.D., McDougall I.R., Sisson J.C. Perspective: The case against radioiodine remnant ablation in patients with well-differentiated thyroid carcinoma. J Nucl Med. 2008;49(8):1395-1397. doi:10.2967/jnumed.108.052654.
66. Gilliland F.D., Hunt W.C., Morris D.M., Key C.R. Prognostic factors for thyroid carcinoma: A populationbased study of 15 698 cases from the Surveillance, Epidemiology, and End Results (SEER) program 1973-1991. Cancer. 1997;79(3):564-573. (Pubitemid 27051783)
67. Hundahl S.A., Fleming I.D., Fremgen A.M., Menck H.R. A National Cancer Data Base report on 53 856 cases of thyroid carcinoma treated in the US, 1985-1995. Cancer. 1998;83(12):2638-2648. (Pubitemid 29019586)
68. Chow S.M., Au K.H., Choy T.S., et al. Health-related quality-of-life study in patients with carcinoma of the thyroid after thyroxine withdrawal for whole body scanning. Laryngoscope. 2006;116(11):2060-2066.
69. Rubino C., De Vathaire F., Dottorini M.E., et al. Second primary malignancies in thyroid cancer patients. Br J Cancer. 2003;89(9):1638-1644. (Pubitemid 37464133)
70. Sawka A.M., Thabane L., Parlea L., et al. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: A systematic review and meta-analysis. Thyroid. 2009;19(5):451-457.
71. Rosário P.W., Borges M.A., Purisch S. Preparation with recombinant human thyroid-stimulating hormone for thyroid remnant ablation with 131I is associated with lowered radiotoxicity. J Nucl Med. 2008;49(11):1776-1782.
72. Luster M., Clarke S.E., Dietlein M., et al European Association of Nuclear Medicine (EANM). Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008;35(10):1941-1959.
73. 131I: practice recommendations of the American Thyroid Association. Thyroid. 2011;21(4):335-346.